(Q40561886)

2 July 2019

title

Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity (English)

1 reference

2 July 2019

Maryalice Stetler-Stevenson

1 reference

2

Maryalice Stetler-Stevenson

1 reference

2 July 2019

Elaine Jaffe

3

Elaine S Jaffe

1 reference

2 July 2019

Wyndham H. Wilson

6

Wyndham Wilson

1 reference

2 July 2019

Thomas Waldmann

7

Thomas A Waldmann

1 reference

2 July 2019

Seth M Steinberg

5

Seth M Steinberg

1 reference

2 July 2019

author name string

Robert J Kreitman

1

1 reference

2 July 2019

Kevin C Conlon

4

1 reference

2 July 2019

Ira Pastan

8

1 reference

2 July 2019

language of work or name

English

0 references

publication date

8 September 2015

1 reference

2 July 2019

published in

Clinical Cancer Research

1 reference

2 July 2019

volume

22

1 reference

2 July 2019

issue

2

1 reference

2 July 2019

page(s)

310-318

1 reference

2 July 2019

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

cites work

1 reference

12 December 2020

Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma

1 reference

12 December 2020

Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer

1 reference

12 December 2020

Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation

1 reference

12 December 2020

Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies

1 reference

12 December 2020

Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma

1 reference

12 December 2020

Global epidemiology of HTLV-I infection and associated diseases

1 reference

12 December 2020

Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.

1 reference

12 December 2020

Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).

1 reference

12 December 2020

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers

1 reference

12 December 2020

VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.

1 reference

12 December 2020

Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting

1 reference

12 December 2020

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

1 reference

12 December 2020

Denileukin diftitox: a novel immunotoxin

1 reference

12 December 2020

Interleukin-2 receptor beta-chain (p70-75) expressed on leukemic cells from adult T cell leukemia patients

1 reference

12 December 2020

Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.

1 reference

12 December 2020

The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia

1 reference

12 December 2020

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

1 reference

12 December 2020

A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin

1 reference

12 December 2020

Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP.

1 reference

12 December 2020

The incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type 1 carriers in Japan

1 reference

12 December 2020

Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma

1 reference

12 December 2020

Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma

1 reference

12 December 2020

Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma: new directions in clinical research

1 reference

12 December 2020

Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model

1 reference

12 December 2020

A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: A single-center experience.

1 reference

12 December 2020

Optimal two-stage designs for phase II clinical trials

1 reference

12 December 2020

Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2.

1 reference

12 December 2020

Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I.

1 reference

12 December 2020

Interleukin 2 receptor (Tac antigen) expression in HTLV-I-associated adult T-cell leukemia.

1 reference

12 December 2020

Adult T-cell leukemia: clinical and hematologic features of 16 cases

1 reference

12 December 2020

Characterization of cellular factors that interact with the human T-cell leukemia virus type I p40x-responsive 21-base-pair sequence

1 reference

12 December 2020

NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus

1 reference

12 December 2020

Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the

1 reference

12 December 2020

Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac.

1 reference

12 December 2020

Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds.

1 reference

12 December 2020

Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptor

1 reference

12 December 2020

The IL-2/IL-2 receptor system: a current overview

1 reference

12 December 2020

Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.

1 reference

12 December 2020

Targeting Pseudomonas exotoxin to hematologic malignancies

1 reference

12 December 2020

Infectious complications and immunodeficiency in patients with human T-cell lymphotropic virus I-associated adult T-cell leukemia/lymphoma

1 reference

12 December 2020

10.1158/1078-0432.CCR-15-1412

Identifiers

DOI

1 reference

2 July 2019

PMC publication ID

6314476

1 reference

2 July 2019

PubMed publication ID

26350263

1 reference

2 July 2019